Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 7/2015

01.07.2015 | Basic Science

Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model

verfasst von: David Kuerten, Sandra Johnen, Nina Harmening, George Souteyrand, Peter Walter, Gabriele Thumann

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The purpose of this study was to investigate the effect of recombinant pigment epithelium-derived factor (rPEDF), secreted by ARPE-19 cells transfected with the human PEDF gene and transplanted subconjunctivally in normal and in rabbits in which corneal neovascularization was elicited by a chemical burn.

Methods

Twenty grey Chinchilla Bastard rabbits were randomly assigned to four groups; neovascularization was induced in groups A, B, and C by alkali cauterization. Seven days later, group A received no cell implantation, non-transfected ARPE-19 cells were implanted subconjunctivally in group B, and PEDF-transfected ARPE-19 cells were implanted subconjunctivally in groups C and D (non-cauterized). In-vivo rPEDF secretion was analyzed by immunoblotting, and ELISA of extracts of conjunctival tissue samples taken at different time points. Digital photographs acquired on days 7, 14, and 21 after cauterization were evaluated for lead vessel length, vascular invasion area, and overall neovascularization rate.

Results

At days 14 and 21 after cauterization, significant differences were observed between groups A, B, and C in lead vessel length (day 21: 5.91 ± 0.45, 5.11 ± 1.22, 3.79 ± 0.59 mm, repectively), vascular invasion area (day 21: 35.5 ± 8.65, 34.86 ± 4.92, 19.2 ± 5.03 mm2 respectively), and rate of corneal neovascularization. Compared to controls, neovascularization was reduced by 37.5 % on day 14 and 47 % on day 21. Analysis of conjunctival tissue extracts showed that rPEDF was secreted by the transplanted PEDF-transfected cells.

Conclusion

Subconjunctivally transplanted, PEDF-transfected ARPE-19 cells secrete rPEDF, which inhibits the corneal neovascularization elicited by alkali cauterization.
Literatur
1.
Zurück zum Zitat Cursiefen C, Wenkel H, Martus P et al (2001) Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 239:514–521PubMedCrossRef Cursiefen C, Wenkel H, Martus P et al (2001) Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 239:514–521PubMedCrossRef
2.
Zurück zum Zitat Qazi YWG, Monson B, Jack Stringham J, Ambati BK (2010) Corneal transparency: genesis, maintenance and dysfunction. Brain Res Bull 25:98–210 Qazi YWG, Monson B, Jack Stringham J, Ambati BK (2010) Corneal transparency: genesis, maintenance and dysfunction. Brain Res Bull 25:98–210
3.
Zurück zum Zitat Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H (1998) Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol 141(5):1277–1286PubMedCentralPubMedCrossRef Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H (1998) Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol 141(5):1277–1286PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12(4):242–249PubMedCrossRef Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12(4):242–249PubMedCrossRef
6.
Zurück zum Zitat Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse F, Wiegand S, Dana M, Streilein J (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45(8):2666–2673PubMedCrossRef Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse F, Wiegand S, Dana M, Streilein J (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45(8):2666–2673PubMedCrossRef
7.
Zurück zum Zitat Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR (2009) Subconjunctival injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 50(4):1659–1665. doi:10.1167/iovs. 08-1997 PubMedCrossRef Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR (2009) Subconjunctival injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 50(4):1659–1665. doi:10.​1167/​iovs.​ 08-1997 PubMedCrossRef
8.
Zurück zum Zitat Bollinger KE, Smith SD (2009) Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant. Curr Opin Ophthalmol 20(2):99–103PubMedCrossRef Bollinger KE, Smith SD (2009) Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant. Curr Opin Ophthalmol 20(2):99–103PubMedCrossRef
9.
Zurück zum Zitat Hashemian MN, Moghimi S, Kiumehr S, Riazi M, Amoli FA (2009) Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res 42(2):90–95. doi:10.1159/000224783 PubMedCrossRef Hashemian MN, Moghimi S, Kiumehr S, Riazi M, Amoli FA (2009) Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res 42(2):90–95. doi:10.​1159/​000224783 PubMedCrossRef
12.
Zurück zum Zitat Mastyugin V, Mosaed S, Bonazzi A, Dunn MW, Schwartzman ML (2001) Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res 23(1):1–10PubMedCrossRef Mastyugin V, Mosaed S, Bonazzi A, Dunn MW, Schwartzman ML (2001) Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res 23(1):1–10PubMedCrossRef
13.
Zurück zum Zitat Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B (2000) Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 70(4):419–428. doi:10.1006/exer.1999.0790 PubMedCrossRef Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B (2000) Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 70(4):419–428. doi:10.​1006/​exer.​1999.​0790 PubMedCrossRef
14.
Zurück zum Zitat Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP (1998) Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39(1):18–22PubMed Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP (1998) Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39(1):18–22PubMed
15.
Zurück zum Zitat Qian CXBI, Levinger E, Rootman D (2008) Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27:1090–1092PubMedCrossRef Qian CXBI, Levinger E, Rootman D (2008) Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27:1090–1092PubMedCrossRef
16.
Zurück zum Zitat Perez-Santonja JJ, Campos-Mollo E, Lledo-Riquelme M, Javaloy J, Alio JL (2010) Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and sunitinib (anti-VEGF and anti-PDGF) in an animal model. Am J Ophthalmol 150(4):519–528. doi:10.1016/j.ajo.2010.04.024, e511PubMedCrossRef Perez-Santonja JJ, Campos-Mollo E, Lledo-Riquelme M, Javaloy J, Alio JL (2010) Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and sunitinib (anti-VEGF and anti-PDGF) in an animal model. Am J Ophthalmol 150(4):519–528. doi:10.​1016/​j.​ajo.​2010.​04.​024, e511PubMedCrossRef
17.
Zurück zum Zitat Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA (2008) Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 145(3):424–431. doi:10.1016/j.ajo.2007.11.003 PubMedCrossRef Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA (2008) Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 145(3):424–431. doi:10.​1016/​j.​ajo.​2007.​11.​003 PubMedCrossRef
19.
Zurück zum Zitat Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48(6):2545–2552. doi:10.1167/iovs. 06-0570 PubMedCrossRef Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48(6):2545–2552. doi:10.​1167/​iovs.​ 06-0570 PubMedCrossRef
20.
Zurück zum Zitat Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, Corpuz R, Li B, Hall L, Rangell L, Ferrando R, Lowman H, Peale F, Ferrara N (2007) Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 104(9):3478–3483. doi:10.1073/pnas.0611492104 PubMedCentralPubMedCrossRef Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, Corpuz R, Li B, Hall L, Rangell L, Ferrando R, Lowman H, Peale F, Ferrara N (2007) Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 104(9):3478–3483. doi:10.​1073/​pnas.​0611492104 PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat van der Flier M, Coenjaerts FE, Mwinzi PN, Rijkers E, Ruyken M, Scharringa J, Kimpen JL, Hoepelman AI, Geelen SP (2005) Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis. J Neuroimmunol 160(1–2):170–177. doi:10.1016/j.jneuroim.2004.11.013 PubMedCrossRef van der Flier M, Coenjaerts FE, Mwinzi PN, Rijkers E, Ruyken M, Scharringa J, Kimpen JL, Hoepelman AI, Geelen SP (2005) Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis. J Neuroimmunol 160(1–2):170–177. doi:10.​1016/​j.​jneuroim.​2004.​11.​013 PubMedCrossRef
24.
Zurück zum Zitat Petsoglou C, Balaggan KS, Dart JK, Bunce C, Xing W, Ali RR, Tuft SJ (2013) Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol 97(1):28–32. doi:10.1136/bjophthalmol-2012-302137 PubMedCrossRef Petsoglou C, Balaggan KS, Dart JK, Bunce C, Xing W, Ali RR, Tuft SJ (2013) Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol 97(1):28–32. doi:10.​1136/​bjophthalmol-2012-302137 PubMedCrossRef
26.
33.
Zurück zum Zitat Bock F, Onderka J, Rummelt C, Dietrich T, Bachmann B, Kruse FE, Schlotzer-Schrehardt U, Cursiefen C (2009) Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 50(5):2095–2102. doi:10.1167/iovs. 07-1129 PubMedCrossRef Bock F, Onderka J, Rummelt C, Dietrich T, Bachmann B, Kruse FE, Schlotzer-Schrehardt U, Cursiefen C (2009) Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 50(5):2095–2102. doi:10.​1167/​iovs.​ 07-1129 PubMedCrossRef
34.
Zurück zum Zitat Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232–1239. doi:10.1093/jnci/djm086 PubMedCrossRef Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232–1239. doi:10.​1093/​jnci/​djm086 PubMedCrossRef
35.
Zurück zum Zitat Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33):5180–5186. doi:10.1200/JCO.2007.12.0782 PubMedCrossRef Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33):5180–5186. doi:10.​1200/​JCO.​2007.​12.​0782 PubMedCrossRef
36.
Zurück zum Zitat Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285(5425):245–248PubMedCrossRef Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285(5425):245–248PubMedCrossRef
37.
Zurück zum Zitat Cursiefen C, Colin J, Dana R, Diaz-Llopis M, Faraj LA, Garcia-Delpech S, Geerling G, Price FW, Remeijer L, Rouse BT, Seitz B, Udaondo P, Meller D, Dua H (2012) Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br J Ophthalmol 96(1):3–9. doi:10.1136/bjo.2011.204701 PubMedCrossRef Cursiefen C, Colin J, Dana R, Diaz-Llopis M, Faraj LA, Garcia-Delpech S, Geerling G, Price FW, Remeijer L, Rouse BT, Seitz B, Udaondo P, Meller D, Dua H (2012) Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br J Ophthalmol 96(1):3–9. doi:10.​1136/​bjo.​2011.​204701 PubMedCrossRef
38.
Zurück zum Zitat Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM, Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP, De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443(7114):993–997. doi:10.1038/nature05249 PubMedCentralPubMedCrossRef Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM, Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP, De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443(7114):993–997. doi:10.​1038/​nature05249 PubMedCentralPubMedCrossRef
40.
Zurück zum Zitat Zhang SX, Wang JJ, Gao G, Parke K, Ma JX (2006) Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37(1):1–12. doi:10.1677/jme.1.02008 PubMedCrossRef Zhang SX, Wang JJ, Gao G, Parke K, Ma JX (2006) Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37(1):1–12. doi:10.​1677/​jme.​1.​02008 PubMedCrossRef
41.
Zurück zum Zitat Cai J, Jiang WG, Grant MB, Boulton M (2006) Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 281(6):3604–3613. doi:10.1074/jbc.M507401200 PubMedCrossRef Cai J, Jiang WG, Grant MB, Boulton M (2006) Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 281(6):3604–3613. doi:10.​1074/​jbc.​M507401200 PubMedCrossRef
42.
Zurück zum Zitat Ogata N, Wada M, Otsuji T, Jo N, Tombran-Tink J, Matsumura M (2002) Expression of pigment epithelium-derived factor in normal adult Rat Eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 43:1168–1175PubMed Ogata N, Wada M, Otsuji T, Jo N, Tombran-Tink J, Matsumura M (2002) Expression of pigment epithelium-derived factor in normal adult Rat Eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 43:1168–1175PubMed
43.
Zurück zum Zitat Petros C, Karakousis PC, John SK et al (2001) Localization of epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol Vis 7:154–163 Petros C, Karakousis PC, John SK et al (2001) Localization of epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol Vis 7:154–163
44.
Zurück zum Zitat Kuo CN, Yang LC, Yang CT, Lai CH, Chen MF, Chen CY, Chen CH, Wu PC, Kou HK, Chen YJ, Hung CH, Tsai CB (2009) Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTeraction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis. Exp Eye Res 89(5):678–685. doi:10.1016/j.exer.2009.06.021 PubMedCrossRef Kuo CN, Yang LC, Yang CT, Lai CH, Chen MF, Chen CY, Chen CH, Wu PC, Kou HK, Chen YJ, Hung CH, Tsai CB (2009) Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTeraction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis. Exp Eye Res 89(5):678–685. doi:10.​1016/​j.​exer.​2009.​06.​021 PubMedCrossRef
45.
Zurück zum Zitat Shao C, Sima J, Zhang SX, Jin J, Reinach P, Wang Z, Ma JX (2004) Suppression of corneal neovascularization by PEDF release from human amniotic membranes. Invest Ophthalmol Vis Sci 45(6):1758–1762PubMedCrossRef Shao C, Sima J, Zhang SX, Jin J, Reinach P, Wang Z, Ma JX (2004) Suppression of corneal neovascularization by PEDF release from human amniotic membranes. Invest Ophthalmol Vis Sci 45(6):1758–1762PubMedCrossRef
46.
Zurück zum Zitat Jin J, Ma JX, Guan M, Yao K (2010) Inhibition of chemical cautery-induced corneal neovascularization by topical pigment epithelium-derived factor eyedrops. Cornea 29:1055–1061PubMedCrossRef Jin J, Ma JX, Guan M, Yao K (2010) Inhibition of chemical cautery-induced corneal neovascularization by topical pigment epithelium-derived factor eyedrops. Cornea 29:1055–1061PubMedCrossRef
47.
Zurück zum Zitat Kuo CN, Chen CY, Chen SN, Yang LC, Lai LJ, Lai CH, Chen MF, Hung CH, Chen CH (2013) Inhibition of corneal neovascularization with the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) vector in a Rat corneal experimental angiogenesis model. Int J Mol Sci 14(4):8291–8305. doi:10.3390/ijms14048291 PubMedCentralPubMedCrossRef Kuo CN, Chen CY, Chen SN, Yang LC, Lai LJ, Lai CH, Chen MF, Hung CH, Chen CH (2013) Inhibition of corneal neovascularization with the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) vector in a Rat corneal experimental angiogenesis model. Int J Mol Sci 14(4):8291–8305. doi:10.​3390/​ijms14048291 PubMedCentralPubMedCrossRef
48.
Zurück zum Zitat Bai YJ, Huang LZ, Xu XL, Du W, Zhou AY, Yu WZ, Li XX (2012) Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization. J Pharmacol Exp Ther 342(1):131–139. doi:10.1124/jpet.112.192575 PubMedCrossRef Bai YJ, Huang LZ, Xu XL, Du W, Zhou AY, Yu WZ, Li XX (2012) Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization. J Pharmacol Exp Ther 342(1):131–139. doi:10.​1124/​jpet.​112.​192575 PubMedCrossRef
49.
Zurück zum Zitat Johnen S, Izsvak Z, Stocker M, Harmening N, Salz AK, Walter P, Thumann G (2012) Sleeping beauty transposon-mediated transfection of retinal and iris pigment epithelial cells. Invest Ophthalmol Vis Sci 53(8):4787–4796. doi:10.1167/iovs. 12-9951 PubMedCrossRef Johnen S, Izsvak Z, Stocker M, Harmening N, Salz AK, Walter P, Thumann G (2012) Sleeping beauty transposon-mediated transfection of retinal and iris pigment epithelial cells. Invest Ophthalmol Vis Sci 53(8):4787–4796. doi:10.​1167/​iovs.​ 12-9951 PubMedCrossRef
50.
Zurück zum Zitat Thumann G, Stöcker M, Maltusch C, Salz AK, Barth S, Walter P, Johnen S (2010) High efficiency non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Ther 17:181–189PubMedCrossRef Thumann G, Stöcker M, Maltusch C, Salz AK, Barth S, Walter P, Johnen S (2010) High efficiency non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Ther 17:181–189PubMedCrossRef
52.
Zurück zum Zitat Olleveant NA, Humphris G, Roe B (1999) How big is a drop? A volumetric assay of essential oils. J Clin Nurs 8(3):299–304PubMedCrossRef Olleveant NA, Humphris G, Roe B (1999) How big is a drop? A volumetric assay of essential oils. J Clin Nurs 8(3):299–304PubMedCrossRef
54.
Zurück zum Zitat Grisanti S, Ishioka M, Kosiewicz M, Jiang LQ (1997) Immunity and immune privilege elicited by cultured retinal pigment epithelial cell transplants. Invest Ophthalmol Vis Sci 38(8):1619–1626PubMed Grisanti S, Ishioka M, Kosiewicz M, Jiang LQ (1997) Immunity and immune privilege elicited by cultured retinal pigment epithelial cell transplants. Invest Ophthalmol Vis Sci 38(8):1619–1626PubMed
Metadaten
Titel
Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model
verfasst von
David Kuerten
Sandra Johnen
Nina Harmening
George Souteyrand
Peter Walter
Gabriele Thumann
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 7/2015
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-015-2954-x

Weitere Artikel der Ausgabe 7/2015

Graefe's Archive for Clinical and Experimental Ophthalmology 7/2015 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.